Symbols

PROK

ProKidney·NASDAQ

--(--)

Signals Analysis

Bullish signal 1

Bearish signal 1

Stock Price Surged Significantly

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About PROK

Prokidney Corp.

A US-based biotech company that develops and commercializes novel therapies for chronic kidney disease

Industry

Biological Technology

Established Date

02/25/2021

Listing Date

06/30/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

231

Fiscal Year Ends

12-31

Website

www.prokidney.com

Security Type

Common stock

Office address

2000 Frontis Plaza Blvd., Suite 250, Winston-Salem, NC 27103

Business

Introduction

ProKidney Corp. was incorporated under the laws of the Cayman Islands on February 25, 2021. The Company is a late-stage clinical biotechnology company that has pioneered the development of a first-in-class autologous cell therapy designed to protect kidney function in patients with advanced chronic kidney disease (" CKD ") and diabetes.

Company Financials

EPS

PROK has released its 2025 Q4 earnings. EPS was reported at -0.14, versus the expected -0.15, beating expectations. The chart below visualizes how PROK has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

PROK has released its 2025 Q4 earnings report, with revenue of 225.00K, reflecting a YoY change of 196.05%, and net profit of -40.85M, showing a YoY change of 15.74%. The Sankey diagram below clearly presents PROK's revenue sources and cost distribution.